Literature DB >> 10836317

Prednisone-dependent asthma: inflammatory indices in induced sputum.

M M Pizzichini1, E Pizzichini, L Clelland, A Efthimiadis, I Pavord, J Dolovich, F E Hargreave.   

Abstract

The kinetics of changes in inflammatory indices in induced sputum from eight prednisone dependent asthmatics whose minimum clinical maintenance and exacerbation doses were known were investigated. The study began on the last day of a course of 30 mg prednisone daily for one week. Thereafter, the daily prednisone was reduced in a structured way to below the maintenance dose. This treatment was continued until a clinical exacerbation occurred. Prednisone 30 mg daily was then given again for one week. The mean duration of prednisone reduction was 7.4 weeks and the median dose was 7.5 mg x day(-1). Increases in sputum eosinophils preceded increases in blood eosinophils by 4 weeks and worsening of symptoms and forced expiratory volume in one second by 6 weeks. The clinical exacerbation was also accompanied by sputum neutrophilia and increases in sputum eosinophil cationic protein (ECP), fibrinogen and interleukin (IL)-5. Treatment with prednisone suppressed median sputum eosinophilia (from 16.3 to 0%, p<0.001), decreased sputum ECP (from 7,480 to 700 microg x L(-1), p = 0.01), but did not improve neutrophil numbers, fibrinogen or IL-5. The results show that the reduction of prednisone treatment in prednisone-dependent asthmatics evokes a severe airway eosinophilic inflammatory response. Clinical and blood indices deteriorate later than those in sputum suggesting that sputum examination may be useful to identify the minimum regular dose of prednisone required in these patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10836317     DOI: 10.1183/09031936.99.13101599

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  18 in total

Review 1.  The use of sputum cell counts to evaluate asthma medications.

Authors:  K Parameswaran; F E Hargreave
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

Review 2.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

Review 3.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

4.  Predictors of loss of asthma control induced by corticosteroid withdrawal.

Authors:  Jose Belda; Krishnan Parameswaran; Catherine Lemière; Dennis Kamada; Paul M O'Byrne; Frederick E Hargreave
Journal:  Can Respir J       Date:  2006-04       Impact factor: 2.409

5.  Cough, airway inflammation, and mild asthma exacerbation.

Authors:  A B Chang; V A Harrhy; J Simpson; I B Masters; P G Gibson
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

Review 6.  Human asthma phenotypes: from the clinic, to cytokines, and back again.

Authors:  Nirav R Bhakta; Prescott G Woodruff
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

7.  Airways disease: phenotyping heterogeneity using measures of airway inflammation.

Authors:  Salman Siddiqui; Christopher E Brightling
Journal:  Allergy Asthma Clin Immunol       Date:  2007-06-15       Impact factor: 3.406

8.  Comparison of airway immunopathology of eosinophilic bronchitis and asthma.

Authors:  C E Brightling; F A Symon; S S Birring; P Bradding; A J Wardlaw; I D Pavord
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

9.  The relationship between eosinophilia and airway remodelling in mild asthma.

Authors:  S J Wilson; H M Rigden; J A Ward; M Laviolette; N N Jarjour; R Djukanović
Journal:  Clin Exp Allergy       Date:  2013-12       Impact factor: 5.018

10.  Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma.

Authors:  Chang-Keun Kim
Journal:  Korean J Pediatr       Date:  2013-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.